2024
DOI: 10.1186/s12933-024-02243-w
|View full text |Cite
|
Sign up to set email alerts
|

Glycemic control and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: insight from ventricular remodeling using cardiac MRI

Ke Shi,
Ge Zhang,
Hang Fu
et al.

Abstract: Background Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) commonly coexist, and the combination of these two diseases indicates a considerably poorer outcome than either disease alone. Therefore, glycemic control should be carefully managed. The present study aimed to e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…Regarding average changes in HbA1c levels, tirzepatide demonstrated both non-inferiority and superiority to semaglutide at all doses [ 80 , 81 ]. HbA1c is crucial for assessing diabetes severity and HF development risk [ 82 ]. Tirzepatide may improve glycemic control by directly and indirectly affecting the pancreas and other tissues.…”
Section: Heart Failurementioning
confidence: 99%
“…Regarding average changes in HbA1c levels, tirzepatide demonstrated both non-inferiority and superiority to semaglutide at all doses [ 80 , 81 ]. HbA1c is crucial for assessing diabetes severity and HF development risk [ 82 ]. Tirzepatide may improve glycemic control by directly and indirectly affecting the pancreas and other tissues.…”
Section: Heart Failurementioning
confidence: 99%